For Research & Educational Discussion Only. Not Medical Advice
Baseline · Research Archive
A member-supported educational community. Every compound gets a plain-language guide of what the studies actually showed and where the evidence runs out, and every guide opens onto its own forum, so the reference material and the argument about it live in one place.
Research and educational discussion only — not medical advice
Actin-sequestering peptide
A naturally occurring actin-binding peptide with genuine early clinical work in eye and wound indications. "TB-500" as sold is usually a fragment, not the full peptide, and the two are routinely conflated.
Ghrelin receptor agonist / growth hormone secretagogue
A selective growth hormone secretagogue that reached phase II for postoperative ileus and was discontinued after missing its endpoints. A useful case study in what a negative trial looks like.
Growth hormone-releasing hormone (GHRH) analogue
A GHRH analogue with early human pharmacokinetic data and no efficacy programme. The DAC and non-DAC versions are pharmacologically very different and are constantly conflated.
Immunomodulatory peptide
An immunomodulatory peptide approved in some countries for hepatitis B and studied in sepsis and oncology. Genuinely contested: real trials exist and they disagree.
ACTH fragment analogue / neuropeptide
An ACTH(4-10) analogue approved in Russia for stroke and cognitive indications, with a literature that is largely Russian-language and difficult to appraise from outside.
GLP-1, GIP and glucagon receptor triple agonist
A triple incretin agonist with phase 2 obesity results larger than anything before it, and no completed phase 3. The most interesting unfinished story in the class.
Amylin receptor agonist
A long-acting amylin analogue, mostly studied in combination with semaglutide. A different satiety pathway to the incretins, which is the point of it.
Mitochondria-targeting tetrapeptide
A cardiolipin-binding peptide with real phase 3 programmes and a mixed record. Genuinely contested rather than merely unproven.
Growth hormone-releasing hormone (GHRH) analogue
The shortest active GHRH fragment. Once approved, withdrawn commercially rather than for safety, and now mostly encountered as a compounded preparation.
Ghrelin receptor agonist / growth hormone secretagogue
An early growth hormone secretagogue, notable mostly for producing intense hunger and for raising cortisol and prolactin alongside GH.
Growth hormone C-terminal fragment
A growth hormone fragment that completed a phase 2b obesity trial and did not beat placebo. One of the few entries here with a proper negative result.
Kisspeptin receptor (KISS1R) agonist
The upstream trigger of the reproductive axis, with genuine ongoing academic human research. One of the more scientifically respectable entries at this end of the ladder.
Tuftsin analogue / anxiolytic neuropeptide
A Russian-registered anxiolytic peptide with the same appraisal problem as Semax: a real literature that is largely inaccessible to outside review.
Dual glucagon and GLP-1 receptor agonist
A dual glucagon/GLP-1 agonist in phase 3 for obesity and for MASH. Real trials, real sponsor, no approval anywhere yet, and the phase 3 readouts that matter are not published.
Dual glucagon and GLP-1 receptor agonist (oxyntomodulin analogue)
An oxyntomodulin analogue developed primarily in China, further along the regulatory path there than anywhere else. Its approval status is the thing people most often get wrong about it.
Nonapeptide hormone (posterior pituitary)
An approved obstetric drug with a very large literature, and a second life as a social and behavioural intervention where the evidence is far weaker than the popular account of it.
Human cathelicidin antimicrobial peptide
The only human cathelicidin, with a very large basic-science literature and a small clinical one. Its dual role, antimicrobial and immunomodulatory, is also why its effects are hard to predict.
Twenty-eight-residue neuropeptide
A well characterised endogenous neuropeptide with an enormous basic literature, and a clinical history dominated by one contested and heavily publicised COVID-19 programme.
Growth hormone secretagogue (ghrelin receptor agonist)
A ghrelin receptor agonist with real human pharmacology behind it, approved in Japan as a diagnostic agent, and zero registered trials for anything people actually use it for.
Endogenous antioxidant tripeptide
The body's main intracellular antioxidant, sold widely as an injectable and oral skin-lightening agent. The biology is not in question. The cosmetic claim rests on small trials, and the injectable route on none.
Dinucleotide coenzyme, not a peptide
An essential coenzyme in every cell, sold as an IV drip and as oral precursors for ageing. The precursors demonstrably raise blood NAD+. Whether raising it does anything for a person is a separate question with much thinner answers.
Vial imagery throughout this archive is illustration. Nothing here is a product, nothing is offered for sale, and nothing on this site is intended for human use. Guides describe what the published research reports; they do not describe what anyone should do. The community rules explain how that line is enforced.
